US 12,331,092 B2
Leucine-rich ALPHA2 glycoprotein composition
Shigeo Takayama, Tokyo (JP); Tetsuji Naka, Ibaraki (JP); and Satoshi Serada, Ibaraki (JP)
Assigned to SEKISUI MEDICAL CO., LTD., Tokyo (JP); and NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, Ibaraki (JP)
Appl. No. 17/282,325
Filed by SEKISUI MEDICAL CO., LTD., Tokyo (JP); and NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, Ibaraki (JP)
PCT Filed Oct. 8, 2019, PCT No. PCT/JP2019/039565
§ 371(c)(1), (2) Date Apr. 1, 2021,
PCT Pub. No. WO2020/075692, PCT Pub. Date Apr. 16, 2020.
Claims priority of application No. 2018-190904 (JP), filed on Oct. 9, 2018.
Prior Publication US 2022/0127314 A1, Apr. 28, 2022
Int. Cl. C07K 14/47 (2006.01); G01N 33/68 (2006.01)
CPC C07K 14/473 (2013.01) [G01N 33/6803 (2013.01)] 10 Claims
 
1. A leucine-rich α2 glycoprotein solution, comprising:
leucine-rich α2 glycoprotein;
a preservative;
a glycoprotein other than LRG, or a peptide;
a non-ionic surfactant;
a buffer;
a metal salt;
and
water,
wherein pH of the solution is 7.8 to 9.0,
concentration of the metal salt of the solution is 300 mM to 600 mM,
90% or more of the leucine-rich α2 glycoprotein contained in the solution containing the leucine-rich α2 glycoprotein is maintained without being decomposed or without a structural change for 29 days at 37° C., and
said solution is suitable for use as a calibration sample solution for measuring leucine-rich α2 glycoprotein.